English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Validation of a Novel Non-Invasive Urine Exosome Gene Expression assay to predict High-grade prostate cancer in patients undergoing initial biopsy with an equivocal PSA. James McKiernan*, Michael Donovan, NYC, NY, Vince O'Neill, Cambridge, MA, Stefan Bentink, Mikkel Noerholm, Martinsried, Germany, Susan Belzer, St. Paul, MN, Johan Skog, Cambridge, MA, Alan Partin, Baltimore, MD, Gerald Andriole, St. Louis, MO, Gordon Brown, Vorhees, NJ, James Cochran, Dallas, TX, John Wei, Livonia, MI, Ian Thompson, San Antonio, TX, Peter Carroll, San Francisco, CA

the journal of urology/the journal of urology

PII-LBA2 VALIDATION OF A NOVEL NON-INVASIVE URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER IN PATIENTS UNDERGOING INITIAL BIOPSY WITH AN EQUIVOCAL PSA.